The maker of EpiPen has agreed to pay the government $465 million after allegedly overcharging for the medicine
AP
Mylan, the marker of the EpiPen, has agreed to pay the federal government a $465 million settlement after it allegedly overcharged government healthcare agencies for the medicine, according to a release from the firm.
Mylan had underpaid Medicare and Medicaid by classifying the EpiPen as a generic drug. Generic drugs are subject to a 13% rebate from the maker to Medicaid and Medicare, rather than a 23.1% rebate for brand name drugs.
"This agreement is another important step... Читать дальше...